Last reviewed · How we verify

Antiandrogen Therapy

M.D. Anderson Cancer Center · Phase 3 active Small molecule

Antiandrogen Therapy is a Androgen receptor antagonist / Hormonal therapy Small molecule drug developed by M.D. Anderson Cancer Center. It is currently in Phase 3 development for Metastatic castration-resistant prostate cancer, Hormone-sensitive prostate cancer. Also known as: ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment.

Antiandrogen therapy blocks the effects of androgens (male hormones) by inhibiting androgen receptor signaling, thereby slowing or stopping the growth of androgen-dependent cancer cells.

Antiandrogen therapy blocks the effects of androgens (male hormones) by inhibiting androgen receptor signaling, thereby slowing or stopping the growth of androgen-dependent cancer cells. Used for Metastatic castration-resistant prostate cancer, Hormone-sensitive prostate cancer.

At a glance

Generic nameAntiandrogen Therapy
Also known asADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment
SponsorM.D. Anderson Cancer Center
Drug classAndrogen receptor antagonist / Hormonal therapy
TargetAndrogen receptor (AR)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Antiandrogens work by competitively binding to androgen receptors on cancer cells or by reducing androgen production, preventing testosterone and dihydrotestosterone from activating growth pathways. This approach is particularly effective in hormone-sensitive cancers where androgen signaling drives proliferation. The therapy may be used alone or in combination with other hormonal agents or chemotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Antiandrogen Therapy

What is Antiandrogen Therapy?

Antiandrogen Therapy is a Androgen receptor antagonist / Hormonal therapy drug developed by M.D. Anderson Cancer Center, indicated for Metastatic castration-resistant prostate cancer, Hormone-sensitive prostate cancer.

How does Antiandrogen Therapy work?

Antiandrogen therapy blocks the effects of androgens (male hormones) by inhibiting androgen receptor signaling, thereby slowing or stopping the growth of androgen-dependent cancer cells.

What is Antiandrogen Therapy used for?

Antiandrogen Therapy is indicated for Metastatic castration-resistant prostate cancer, Hormone-sensitive prostate cancer.

Who makes Antiandrogen Therapy?

Antiandrogen Therapy is developed by M.D. Anderson Cancer Center (see full M.D. Anderson Cancer Center pipeline at /company/m-d-anderson-cancer-center).

Is Antiandrogen Therapy also known as anything else?

Antiandrogen Therapy is also known as ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment.

What drug class is Antiandrogen Therapy in?

Antiandrogen Therapy belongs to the Androgen receptor antagonist / Hormonal therapy class. See all Androgen receptor antagonist / Hormonal therapy drugs at /class/androgen-receptor-antagonist-hormonal-therapy.

What development phase is Antiandrogen Therapy in?

Antiandrogen Therapy is in Phase 3.

What are the side effects of Antiandrogen Therapy?

Common side effects of Antiandrogen Therapy include Hot flashes, Fatigue, Gynecomastia, Sexual dysfunction, Hepatotoxicity.

What does Antiandrogen Therapy target?

Antiandrogen Therapy targets Androgen receptor (AR) and is a Androgen receptor antagonist / Hormonal therapy.

Related